Course: Developments With BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
CME Credits: 0.00
Released: 2024-11-27
This virtual, interactive activity is designed to help you optimize the development of treatment plans with your patients with multiple myeloma, incorporating the latest data on current and emerging BCMA-directed approaches such as CAR T-cell therapy and bispecific antibodies. It is also intended to provide effective strategies to identify and mitigate potential bispecific antibody-associated adverse events, as well as expert appraisal of the therapeutic potential of ongoing lines of clinical investigation with bispecific antibody therapy. The incorporation of multiple clinical case scenarios, illustrative animations, and didactic presentation will help to bring key messages home.
View Full Course